Literature DB >> 8750185

Expression of the CD44 adhesion molecule in tumours of the central and peripheral nervous system.

G H Baltuch1, N de Tribolet, E G Van Meir.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8750185     DOI： 10.1007/bf01052622

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  58 in total

1.  CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival.

Authors:  J L Nugent; P A Bunn; M J Matthews; D C Ihde; M H Cohen; A Gazdar; J D Minna
Journal:  Cancer       Date:  1979-11       Impact factor: 6.860

2.  Binding and degradation of hyaluronan by human breast cancer cell lines expressing different forms of CD44: correlation with invasive potential.

Authors:  M Culty; M Shizari; E W Thompson; C B Underhill
Journal:  J Cell Physiol       Date:  1994-08       Impact factor: 6.384

Review 3.  The interaction of hyaluronate with the cell surface: the hyaluronate receptor and the core protein.

Authors:  C B Underhill
Journal:  Ciba Found Symp       Date:  1989

4.  Laminin: a potential inhibitor of rat glioma cell invasion in vitro.

Authors:  A Reith; R Bjerkvig; G J Rucklidge
Journal:  Anticancer Res       Date:  1994 May-Jun       Impact factor: 2.480

5.  Binding of hyaluronic acid to lymphoid cell lines is inhibited by monoclonal antibodies against Pgp-1.

Authors:  J Lesley; R Schulte; R Hyman
Journal:  Exp Cell Res       Date:  1990-04       Impact factor: 3.905

6.  CD44 mediates human glioma cell adhesion and invasion in vitro.

Authors:  A Merzak; S Koocheckpour; G J Pilkington
Journal:  Cancer Res       Date:  1994-08-01       Impact factor: 12.701

7.  Prevention of tumor metastasis formation by anti-variant CD44.

Authors:  S Seiter; R Arch; S Reber; D Komitowski; M Hofmann; H Ponta; P Herrlich; S Matzku; M Zöller
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

8.  Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyaluronate recognition.

Authors:  K Miyake; C B Underhill; J Lesley; P W Kincade
Journal:  J Exp Med       Date:  1990-07-01       Impact factor: 14.307

9.  Regulated expression of exon v6 containing isoforms of CD44 in man: downregulation during malignant transformation of tumors of squamocellular origin.

Authors:  M Salmi; K Grön-Virta; P Sointu; R Grenman; H Kalimo; S Jalkanen
Journal:  J Cell Biol       Date:  1993-07       Impact factor: 10.539

10.  Identification of glioma-associated antigen MUC 2-63 as CD44.

Authors:  P Romeijn; R Lenthall; D Stavrou; D Melcher; H Ladyman; M A Ritter
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640
View more
  5 in total

1.  Hyaluronate receptors mediating glioma cell migration and proliferation.

Authors:  Y Akiyama; S Jung; B Salhia; S Lee; S Hubbard; M Taylor; T Mainprize; K Akaishi; W van Furth; J T Rutka
Journal:  J Neurooncol       Date:  2001-06       Impact factor: 4.130

2.  CD44s-targeted treatment with monoclonal antibody blocks intracerebral invasion and growth of 9L gliosarcoma.

Authors:  S Gunia; S Hussein; D L Radu; K M Pütz; R Breyer; H Hecker; M Samii; G F Walter; A C Stan
Journal:  Clin Exp Metastasis       Date:  1999-05       Impact factor: 5.150

3.  CD44 and p53 immunoexpression patterns in NF1 neoplasms - indicators of malignancy and infiltration.

Authors:  Nicole D Riddle; Lemuel Gorden; Mumtaz V Rojiani; Ardeshir Hakam; Amyn M Rojiani
Journal:  Int J Clin Exp Pathol       Date:  2010-06-12

4.  The hyaluronan receptor RHAMM/IHABP in astrocytoma cells: expression of a tumor-specific variant and association with microtubules.

Authors:  Rixin Zhou; Xiao Wu; Omar Skalli
Journal:  J Neurooncol       Date:  2002-08       Impact factor: 4.130

5.  CD44H is expressed by cells of the oligodendrocyte lineage and by oligodendrogliomas in humans.

Authors:  Corinne Bouvier-Labit; Agnès Liprandi; Gilberte Monti; Jean François Pellissier; Dominique Figarella-Branger
Journal:  J Neurooncol       Date:  2002-11       Impact factor: 4.130
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.